Published • loading... • Updated
Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
Summary by psychedelicalpha.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
FDA Floats Ibogaine Trial Design, Asks Field for Input • Compass Talks Pricing, Label and a Slow Launch • Six More Potential Psychedelic Brand Names, From Compass and Definium • Psychedelic CEOs Take MAHA Stage; Compass Stresses TRD Distinction • New Mexico Nears Medical Psilocybin Launch, but Landlord Rule Sparks Pushback • Other Stories • 1967 LSD Manual Warns Against Ending Sessions Early • Other Headlines
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
